News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
100 Results
Type
Article (16)
Press Release (84)
Section
Business (37)
Deals (7)
Drug Development (9)
FDA (1)
Job Trends (2)
News (49)
Tag
Alliances (2)
Approvals (1)
Autoimmune disease (1)
Best Places to Work (1)
Cancer (7)
Career advice (1)
Clinical research (16)
Collaboration (3)
C-suite (2)
Data (4)
Depression (1)
Earnings (20)
Events (15)
Executive appointments (2)
FDA (1)
GLP-1 (1)
Immunology and inflammation (1)
Immuno-oncology (1)
IPO (6)
Job creations (1)
Leadership (1)
Lung cancer (1)
Mergers & acquisitions (1)
Neuroscience (1)
Patient recruitment (2)
People (22)
Phase 1 (15)
Phase 2 (1)
Phase 3 (1)
Pipeline (11)
Preclinical (1)
Prostate cancer (3)
Psychedelics (1)
Startups (3)
Date
Last 7 days (1)
Last 30 days (4)
Last 365 days (20)
2026 (11)
2025 (14)
2024 (16)
2023 (11)
2022 (24)
2021 (22)
2020 (2)
Location
Asia (3)
California (29)
Europe (3)
North Carolina (1)
Southern California (28)
United States (30)
100 Results for "janux".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development
April 28, 2026
·
5 min read
Press Releases
Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights
May 8, 2026
·
8 min read
Press Releases
Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014
April 17, 2026
·
6 min read
Cancer
BMS Bets $850M on Janux’s Tumor-Activated Drugs, Deepening Cancer Investments
The partnership will allow BMS to advance a T cell–based therapy that is only activated once in the vicinity of a tumor.
January 22, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment
April 2, 2026
·
5 min read
Press Releases
Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
February 27, 2026
·
9 min read
Press Releases
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
February 17, 2026
·
6 min read
Press Releases
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
January 27, 2026
·
6 min read
Press Releases
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
December 24, 2025
·
5 min read
Press Releases
Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors
January 22, 2026
·
5 min read
1 of 10
Next
